JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



First published online December 15, 2009, 10.2967/jnumed.109.067108
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.109.067108v1
51/1/31    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seo, Y.
Right arrow Articles by Hawkins, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seo, Y.
Right arrow Articles by Hawkins, R. A.
Journal of Nuclear Medicine Vol. 51 No. 1 31-36
© 2010 by Society of Nuclear Medicine
doi: 10.2967/jnumed.109.067108

Clinical Investigation

In Vivo Tumor Grading of Prostate Cancer Using Quantitative 111In-Capromab Pendetide SPECT/CT

Youngho Seo1–3, Carina Mari Aparici1,4, Matthew R. Cooperberg4,5, Badrinath R. Konety4,5 and Randall A. Hawkins1,2

1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, California; 2 Joint Graduate Group in Bioengineering, University of California, San Francisco and Berkeley, California; 3 Department of Radiation Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California; 4 San Francisco Veterans Affairs Medical Center, San Francisco, California; and 5 Department of Urology, University of California, San Francisco, California

Correspondence: For correspondence contact: Youngho Seo, Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94143-0946. E-mail: youngho.seo{at}radiology.ucsf.edu

We have developed an in vivo method to quantify antibody uptake using 111In-capromab pendetide SPECT combined with CT (SPECT/CT). Our goal was to evaluate this method for potential grading of prostate tumors. Methods: Our phantom experiments focused on the robustness of an advanced iterative reconstruction algorithm that involves corrections for photon attenuation, scatter, and geometric blurring caused by radionuclide collimators. The conversion factors between image values and tracer concentrations (in Bq/mL) were calculated from a uniform phantom filled with an aqueous solution of 111InCl3 using the same acquisition protocol and reconstruction parameters as for patient studies. In addition, the spatial resolution of the reconstructed images was measured from a point source phantom. The measured spatial resolution was modeled into a point-spread function, and the point-spread function was implemented in a deconvolution-based partial-volume-error correction algorithm. The recovery capability to correctly estimate true tracer concentrations was tested using prostatelike and bladderlike lesion phantoms fitted in the modified National Electrical Manufacturers Association/International Electrotechnical Commission body phantom. Patients with biopsy-proven prostate cancer (n = 10) who underwent prostatectomy were prospectively enrolled in the preoperative SPECT/CT studies at the San Francisco Veterans Affairs Medical Center. The CT portion of SPECT/CT was used to generate CT-based attenuation maps and as an anatomic localization tool for clinical interpretation. Pathologic Gleason grades were compared with in vivo antibody uptake value (AUV) normalized by injected dose, effective half-life, and injection-scan time difference. AUVs were calculated in each lobe of the prostate gland with cylindric volumes of interest having dimensions of 1.5 cm in both diameter and height. Results: Reconstructed SPECT images further corrected by the deconvolution-based partial-volume-error correction could recover tracer concentrations up to 90% of true values in measurements of phantom volumes as small as 7.77 mL. From patient studies, there was a statistically significant correlation ({rho} = 0.71, P = 0.033) between higher AUVs (from either left or right lobe) and higher components of pathologic Gleason scores. Conclusion: Our results strongly indicate potential for noninvasive prostate tumor grading using quantitative 111In-capromab pendetide SPECT/CT.

Key Words: prostate cancer • capromab pendetide • SPECT • SPECT/CT • quantification • tracer quantification • quantitative SPECT • prostate-specific membrane antigen (PSMA)

COPYRIGHT © 2010 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2010 51: 9A-10A. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2010 by the Society of Nuclear Medicine.